ArticleTranslational andrology and urology2026
Intermittent androgen deprivation therapy for biochemical recurrence or prostate-specific antigen (PSA) persistence after radical prostatectomy: efficacy and prognostic factors.
Article in Translational andrology and urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The optimal protocol for intermittent androgen deprivation therapy (IAD) in managing biochemical recurrence (BCR) and persistent prostate-specific antigen (PSA) levels after radical prostatectomy (RP) remains undefined. This study aimed to introduce a novel IAD protocol, conduct an initial assessment of the protocol's effectiveness in real-world settings, and develop a risk-based model to identify patients most likely to benefit from this approach. Methods: This study included 175 post-RP patients receiving IAD, with a median follow-up of 44.77 months [interquartile range (IQR), 31.87-69.50 months] post-androgen deprivation therapy (ADT). The IAD protocol used a PSA threshold of 0.2 ng/mL to define progression during the first intermittent phase. Key clinical and pathological parameters, including PSA kinetics and testosterone levels, were analyzed. Cox regression assessed the duration of the first intermittent phase, while logistic regression analyses identified factors associated with the efficacy of ADT in the second treatment phase. Nomograms were developed for clinical applications. Results: Cox regression analysis revealed that the duration of the first intermittent phase was significantly associated with castration-resistant prostate cancer (CRPC)-free survival. Pathological Gleason grade group 5 (GGG 5) was a risk factor for a shorter first intermittent phase, while PSA doubling time (PSADT) ≥3.32 months and testosterone doubling time (TDT) ≥5.03 months were protective factors. Logistic regression identified combined metformin use, testosterone recovery to normal levels during the first intermittent phase, and a PSA response rate ≥90% after the first luteinizing hormone-releasing hormone (LHRH) injection in the first treatment cycle as protective factors against a PSA response rate <90% during salvage ADT in the second treatment phase [area under the curve (AUC) =0.84]. Conclusions: The duration of the first intermittent phase was a significant predictor of CRPC-free survival. PSADT, TDT, and pathological GGG 5 were independent predictors of this duration. Furthermore, combined metformin use appeared to preserve ADT sensitivity in patients with PSA progression during the first intermittent phase.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.